Yazar "Ergin, Sevgi" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    Antibody responses post-booster covid-19 vaccination: insights from a single-center prospective cohort study
    (2024) Dinç, Harika Öykü; Can, Günay; Budak, Beyhan; Daşdemir, Ferhat Osman; Keskin, Elif; Kırkoyun Uysal, Hayriye; Aydoğan, Okan; Balkan, İlker İnanç; Karaali, Rıdvan; Ergin, Sevgi; Saltoğlu, Neşe; Kocazeybek, Bekir
    The study aimed to evaluate the effect of booster dose COVID-19 vaccines on prevention and humoral immune response in individuals with different vaccination schemes during the period BA.4 and BA.5 omicron sub-variants were globally dominant. The study included 146 individuals who preferred different vaccination schemes for booster doses. Anti-spike/RBD-IgG and neutralizing antibody levels were measured 28 days after the booster dose vaccination upon their consent. There is no significant difference between median antibody titers detected according to different vaccination schemes. SARS-CoV-2 neutralizing antibody inhibition percentages were detected significantly higher in serum samples before and after the last booster dose in 2 BNT162b2+1 BNT162b2(99.42 %), 2 BNT162b2 + 2 BNT162b2(99.42 %), and 2 BNT162b2 + 3 BNT162b2(99.42 %) vaccination schemes (p = 0.004, p = 0.044, p = 0.002,respectively). The study indicated that a booster vaccination dose provides a high level of protection against severe COVID-19 and death. We think that the variant-specific pancoronavirus vaccines will be necessary to protect against breakthrough infections.
  • Küçük Resim
    Öğe
    Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs
    (Elsevier Inc., 2022) Saltoğlu, Neşe; Dinç, Harika Öykü; Balkan, İlker İnanç; Can, Günay; Özbey, Doğukan; Beytur, Ayşe Nur; Keskin, Elif; Budak, Beyhan; Aydoğan, Okan; Mete, Bilgül; Karaali, Rıdvan; Ergin, Sevgi
    The objective of our study was to evaluate the antibody responses of health care workers (HCWs) who were vaccinated with booster dose BNT162b2 6 months after 2 doses of the CoronoVac vaccine. The study included 318 HCWs vaccinated with inactive CoronaVac SARS-CoV-2 vaccine in 2 doses. Anti-spike/RBD IgG levels were measured immediately before and 1 month after the booster dose. In the sixth month after CoronaVac vaccination, the median of antibody levels of 1212.02 AU/ML, while it was 9283 AU/mL after BNT162b2 vaccination. IgG antibody titers of over 1050 AU/mL (which is equivalent to 1:80 dilution in the plaque reduction neutralization test) were detected in HCWs 15.09% and 97.8%, respectively. Our results showed that antibody titers increased 8-fold after the booster dose. We believe that the administration of the mRNA vaccine as a booster dose can provide more effective protection against COVID-19 infection, especially in individuals with risk factors.
  • Küçük Resim Yok
    Öğe
    Investigation of obesity-related HAdV-36 in NAFLD patients: A case-control study
    (Verlag Klinisches Labor GmbH, 2023) Dinç, Harika Öykü; Çizmecigil, Utku; Sulu, Cem; Yıldırım, Süleyman; Turgut, Başar C.; Sirekbasan, Serhat; Aydoğan, Okan; Durman, Tunahan; Özbey, Doğukan; Aslan, Beyza; Sonsuz, Abdullah; Zengin, Kağan; Yumuk, Volkan Demirhan; Yılmaz, Aysun; Turan, Nuri; Yılmaz, Hüseyin; Tufan Koçak, Banu; Sarıbaş, Suat; Ergin, Sevgi; Kocazeybek, Bekir
    Background: HAdV-36 leads to adipocyte proliferation of adipose tissue through E4orf1 gene, leading to the development of obesity and related diseases. We aimed to investigate the presence and any association of HAdV-36 in non-alcoholic fatty liver disease (NAFLD) patients Methods: The patient group was composed of 116 patients; 30 obese patients with NAFLD (BMI > 30 kg/m2), 30 patients with Diabetes Mellitus (DM)+NAFLD (BMI > 30 kg/m2), 16 patients with NAFLD (BMI < 30 kg/m2), and operated obese group with NAFLD (BMI > 30 kg/m2). The control group comprised 81 non-obese healthy adults. Liver adipose tissue samples were obtained in 30 operated NAFLD patients. HAdV-36-DNA, HAdV-36 neutralizing antibodies, serum lipid, and adipokine levels were analyzed. Results: HAdV-36 neutralizing antibodies (HAdV-36 Ab-positive) were detected in 10/116 and 2/81 participants in the study and control groups, respectively; the difference was statistically significant (p < 0.005). LDL, total cholesterol but not adipokine levels were found to be significantly higher in HadV-36 Ab-positive patients (p < 0.05). While HAdV-36 was identified as a risk factor with OR = 4.11 in univariate analyses, there was no significant difference in binary logistic regression analysis. HAdV-36-DNA was detected in the adipose tissue samples of two patients. Conclusions: We suggest that the presence of HAdV-36 may lead to the development of obesity with the increase in adipose tissue, and diseases such as hyperlipidemia, NAFLD, DM, and metabolic syndrome may develop on the basis of chronic inflammation caused by obesity. Thus, HAdV-36 may be a plausible risk factor for the development of NAFLD.
  • Küçük Resim
    Öğe
    Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: Booster required
    (Springer London Ltd, 2023) Balkan, İlker İnanç; Dinç, Harika Öykü; Can, Günay; Karaali, Rıdvan; Özbey, Doğukan; Çağlar, Bilge; Beytur, Ayşe Nur; Keskin, Elif; Budak, Beyhan; Aydoğan, Okan; Mete, Bilgül; Ergin, Sevgi; Kocazeybek, Bekir; Saltoğlu, Neşe
    Aims Despite high vaccination rates, increasing case numbers continue to be reported with the identification of new variants of concern, and the issue of durability of the vaccine-induced immune response remains hot topic. Real-life data regarding time-dependent immunogenicity of inactivated COVID-19 vaccines are scarce. We aimed to investigate the changes in the antibody at the different times after the second dose of the CoronaVac vaccine. Methods The study included 175 HCWs vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses. Anti-spike/RBD IgG levels were measured first, third, and sixth months after the second dose. Chemiluminescent microparticle immunoassay (IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test, was used. Results Mean age of the participants was 38 +/- 11.23 years (range between 22 and 66) of whom 119 (63.9%) were female, and 56 (32%) were male. Dramatic reductions were demonstrated in median antibody levels particularly in the infection-naive group, comprising 138 HCWs compared to those with prior history of COVID-19 infection (n = 37) (p < 0.001). There was no difference between the two groups in terms of age, gender, blood groups, BMI, and comorbid diseases. Conclusions While antibody positivity remained above 90% in the 6th month after two doses of inactivated vaccine in HCWs, the median titers of neutralizing antibodies decreased rapidly. The decrease was more rapid and significant in those with no history of prior COVID-19 infection. In this critical phase of the pandemic, where we are facing the dominance of the Omicron variant after Delta, booster doses have become vital.